Search over 3,000 reports

    Hepatitis C - Competitive Landscape, Market and Pipeline Analysis 2017

    Hepatitis C - Competitive Landscape, Market and Pipeline Analysis 2017
    Date: Sep, 2017
    Type: Pharmaceutical Industry Report
    Pages: 234
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DISR0014

    Hepatitis C - Competitive Landscape, Market and Pipeline Analysis 2017 report provides comprehensive insights about different therapeutic drugs for the treatment of Hepatitis C. A key objective of the report is to provide market and competitive landscape; and pipeline products for Hepatitis C.

    The report provides in-depth details of 20+ marketed products, which are currently leading the market. It also provides the therapeutic details of the marketed product in this area, along with their historical and forecasted sales till 2022. It also covers the 15+ companies, which are active in this field with 30+ therapeutic pipeline drugs that are currently under development for the treatment of Hepatitis C including their comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Pre-clinical and Discovery stage products. Additionally, Forecasted sales of Phase III drugs are also incorporated in the report. A separate section for inactive products is also included in the report.

    Comparative analysis of therapeutic drugs at various stages and their therapeutic assessment by product type and molecule type provides additional and vital details of the pipeline drugs. The report also provides the market drivers and barriers for Hepatitis C drugs for the enhanced pipeline of Hepatitis C. Information on various technologies involved in the development of pipeline therapeutics along with all the collaborations and agreements of the respective company brings added the advantage of this report. Patent and Financing details related to the products are also provided.

    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts. Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

     

     

    Introduction     

    Collaborations 

    Technology       

    Overview           

    Signs and Symptoms     

    Pathogenesis    

    Diagnosis            

    Marketed Drugs              

    Vosevi: Gilead Sciences              

    Product Description       

    Research and Development       

    Product Development Activities               

    Drug Sales          

    Daklinza: Bristol-Myers Squibb

    Product Description       

    Research and Development       

    Product Development Activities               

    Drug Sales          

    Ximency: Bristol-Myers Squibb

    Product Description       

    Research and Development       

    Product Development Activities               

    Sunvepra: Bristol-Myers Squibb              

    Product Description       

    Research and Development       

    Product Development Activities               

    Drug Sales          

    Pegasys: Roche

    Product Description       

    Research and Development       

    Product Development Activities               

    Drug Sales          

    Sovaldi: Gilead Sciences             

    Product Description       

    Research and Development       

    Product Development Activities               

    Drug Sales          

    Other Marketed Drug Profiles in detailed report

    Clinical Pipeline Landscape       

    Comparative Analysis   

    Late Stage Products (Filed & Phase III) 

    Comparative Analysis    

    Danoprevir: Roche         

    Product Description       

    Research and Development       

    Product Development Activities               

    Glecaprevir/Pibrentasvir (G/P): AbbVie              

    Product Description       

    Research and Development       

    Product Development Activities               

    Other Drug Profiles in detailed report

    Mid Stage Products (Phase II)   

    Comparative Analysis   

    JNJ-4178: Janssen           

    Product Description       

    Research and Development       

    Product Development Activities               

    P-1101: PharmaEssentia              

    Product Description       

    Research and Development       

    Product Development Activities               

    Other Drug Profiles in detailed report

    Early Stage Products (Phase I)   

    Comparative Analysis    

    AVR560: AllaChem         

    Product Description       

    Research and Development       

    Product Development Activities               

    CC-31244: Cocrystal Pharma       

    Product Description       

    Research and Development       

    Other Drug Profiles in detailed report

    Pre-clinical and Discovery          

    Therapeutic Assessment: Clinical Pipeline Products      

    Assessment by Monotherapy Products

    Assessment by Combination Products  

    Assessment by Route of Administration               

    Assessment by Stage and Route of Administration          

    Assessment by Stage and Molecule Type            

    Inactive Products            

    Dormant Products          

    Comparative Analysis    

    Discontinued Products 

    Comparative Analysis    

    Drivers and Barriers       

    Appendix           

     

    Table 1: Total Products for Hepatitis C    

    Table 2: Late Stage Products (Filed and Phase III)             

    Table 3: Mid Stage Products (Phase II)   

    Table 4: Early Stage Products (Phase I)  

    Table 5: List of Pre-clinical and Discovery Products           

    Table 6: Assessment by Monotherapy Products

    Table 7: Assessment by Combination Therapy Products

    Table 8: Assessment by Route of Administration              

    Table 9: Assessment by Stage and Route of Administration         

    Table 10: Assessment by Stage and Molecule Type         

    Table 11: List of Dormant Products          

    Table 12: List of Discontinued Products  

    Figure 1: Course of Illness with Hepatitis C           

    Figure 2: Global Epidemiology of Hepatitis C       

    Figure 3: HCV Life Cycle and Pathogenesis           

    Figure 4: Vosevi, Historical & Forecasted Sales (million USD)        

    Figure 5: Daklinza, Historical & Forecasted Sales (million USD)     

    Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)  

    Figure 7: Pegasys, Historical & Forecasted Sales (million USD)     

    Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)       

    Other Marketed Drug Sales in detailed report (Figure 9-19).                   

    Figure 20: Total Products for Hepatitis C

    Figure 21: Late Stage Products (Filed and Phase III)         

    Figure 22: Mid Stage Products (Phase II)               

    Figure 23: Early Stage Products (Phase I)              

    Figure 24: Pre-clinical and Discovery Products    

    Figure 25: Assessment by Monotherapy Products           

    Figure 26: Assessment by Combination Therapy Products            

    Figure 27: Assessment by Route of Administration          

    Figure 28: Assessment by Stage and Route of Administration     

    Figure 29: Assessment by Stage and Molecule Type        

    Figure 30: Dormant Products     

    Figure 31: Discontinued Products             

     

    AbbVie
    AllaChem
    Amarillo Biosciences
    Beijing Kawin Technology Share-Holding
    Biotron
    Cocrystal Pharma
    Dongguan HEC TaiGen Biopharmaceuticals
    Janssen (a Johnson & Johnson Company)
    Merck
    Microbio
    PharmaEssentia
    Presidio Pharmaceuticals
    Regulus Therapeutics
    Roche
    TaiGen Biotechnology
    TaiwanJ Pharmaceuticals
    TCM Biotech International
    Trek Therapeutics
    • Single User Price
      $3,250.00
    • Site License Price
      $6,500.00
    • Enterprise Price
      $9,750.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap